Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | GNRHR | P30968 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 7/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | TACR2 | P21452 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 1/20 | 0.34 |
| ▸ | TACR3 | P29371 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26969777 | 0.95 | HTR6 (0.40) | NPY5RHTR6P2RY1RORCGNRHR | |
| SCHEMBL29387124 | 0.90 | HTR6 (0.40) | HTR6P2RY1RORCCCR5NR1I2 | |
| SCHEMBL25232753 | 0.90 | HTR6 (0.40) | HTR6P2RY1RORCCCR5NR1I2 | |
| SCHEMBL25231173 | 0.88 | NPY5R (0.38) | NPY5RP2RY1RORCGNRHRALDH1A1 | |
| SCHEMBL25281945 | 0.85 | HTR6 (0.38) | NPY5RHTR6P2RY1RORCGNRHR | |
| SCHEMBL26969707 | 0.82 | TSHR (0.38) | NPY5RALDH1A1GAAMAPTTACR1 | |
| SCHEMBL26969727 | 0.81 | NPY5R (0.42) | NPY5RGNRHRALDH1A1GAAMAPT | |
| SCHEMBL26969745 | 0.81 | HDAC1 (0.41) | NPY5RHTR6 | |
| SCHEMBL25275703 | 0.81 | ACLY (0.39) | NPY5R | |
| SCHEMBL26969744 | 0.80 | HTR6 (0.40) | NPY5RHTR6P2RY1GNRHRTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | NPY5R 681/4885HTR6 189/4885P2RY1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.